Literature DB >> 26812550

Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

E Daudén1, L Puig2, C Ferrándiz3, J L Sánchez-Carazo4, J M Hernanz-Hermosa5.   

Abstract

Psoriasis is a highly prevalent disease with a major impact on quality of life; therefore, appropriate patient management is mandatory. Given that many issues in psoriasis are controversial and not clearly defined by evidence-based medicine, management of psoriasis is very variable. Expert consensus can generate practical guidelines for optimization of patient care. Much has changed since 2009, when the Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis was published by the Spanish Psoriasis Group (GEP) of the Spanish Academy of Dermatology and Venereology (AEDV). The objective of the present consensus document is to provide the dermatologist with updated recommendations for the evaluation and treatment of patients with moderate-to-severe plaque psoriasis. All active members of the GEP of the AEDV were invited to participate in the survey. The final group comprised 46 members from various areas of Spain and with substantial experience in managing psoriasis. A 3-round Delphi process was used to reach consensus. Consistent agreement and consistent disagreement (consensus) required the achievement of at least two of the following three criteria: Criterion 1, which was based on the position occupied by the mean on a scale of 1-9 and an SD <2; Criterion 2, which was based on the median and interquartile range (IQR) on a scale of 1-9; Criterion 3, which considered the percentage of the voting experts on a scale of 1-9. The items studied were definition of severity, therapeutic objectives, indications for systemic treatment and biologic therapy, induction and maintenance periods, therapeutic failure, loss of response, relapse and rebound, continuous and intermittent therapy, screening of patients before treatment, adherence to therapy, follow-up of treatment outcome, combination of drugs, transitioning and associated comorbidities. Consistent agreement or disagreement (consensus) was achieved for 198 items (agreement, 3 criteria 146 items, 2 criteria 43 items; disagreement, 3 criteria 9 items, 2 criteria 0 items) based on the criteria described above. Completion of the Delphi consensus process enabled a broad and experienced group of Spanish psoriasis experts to provide useful and practical guidelines for the management and treatment of patients with moderate-to-severe psoriasis, particularly in areas where evidence is lacking.
© 2016 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2016        PMID: 26812550     DOI: 10.1111/jdv.13542

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  19 in total

Review 1.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

2.  IL17RA gene variants and anti-TNF response among psoriasis patients.

Authors:  A Batalla; E Coto; J Gómez; N Eirís; D González-Fernández; C Gómez-De Castro; E Daudén; M Llamas-Velasco; R Prieto-Perez; F Abad-Santos; G Carretero; F S García; Y B Godoy; L F Cardo; B Alonso; S Iglesias; P Coto-Segura
Journal:  Pharmacogenomics J       Date:  2016-09-27       Impact factor: 3.550

3.  PGRN Suppresses Inflammation and Promotes Autophagy in Keratinocytes Through the Wnt/β-Catenin Signaling Pathway.

Authors:  Rong Tian; You Li; Xu Yao
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

4.  Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice.

Authors:  Selma Atalay; Lara S van der Schoot; Laura Vandermaesen; Lieke J van Vugt; Mascha Eilander; Juul M P A van den Reek; Elke M G J de Jong
Journal:  Acta Derm Venereol       Date:  2021-05-25       Impact factor: 3.875

5.  DNA Copy Number Variation Associated with Anti-tumour Necrosis Factor Drug Response and Paradoxical Psoriasiform Reactions in Patients with Moderate-to-severe Psoriasis.

Authors:  Ancor Sanz-Garcia; Alejandra Reolid; Laura H Fisas; Ester Muñoz-Aceituno; Mar Llamas-Velasco; Antonio Sahuquillo-Torralba; Rafael Botella-Estrada; Jorge García-Martínez; Raquel Navarro; Esteban Daudén; Francisco Abad-Santos; Maria C Ovejero-Benito
Journal:  Acta Derm Venereol       Date:  2021-05-04       Impact factor: 3.875

Review 6.  Treatment Approaches to Moderate to Severe Psoriasis.

Authors:  Paolo Gisondi; Micol Del Giglio; Giampiero Girolomoni
Journal:  Int J Mol Sci       Date:  2017-11-16       Impact factor: 5.923

7.  Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain.

Authors:  Erin Johansson; Mercedes Nuñez; Axel Svedbom; Tatiana Dilla; Susanne Hartz
Journal:  Clinicoecon Outcomes Res       Date:  2018-11-12

8.  A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management.

Authors:  L Grine; M de la Brassinne; P-D Ghislain; T Hillary; J Lambert; S Segaert; F Willaert; J Lambert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-01-02       Impact factor: 6.166

Review 9.  Old and New Biological Therapies for Psoriasis.

Authors:  Kirsten Rønholt; Lars Iversen
Journal:  Int J Mol Sci       Date:  2017-11-01       Impact factor: 5.923

Review 10.  Liver Illness and Psoriatic Patients.

Authors:  Marco Fiore; Sebastiano Leone; Alberto Enrico Maraolo; Emilio Berti; Giovanni Damiani
Journal:  Biomed Res Int       Date:  2018-02-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.